Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00039273 · ClinicalTrials.gov registry record · Phase 2

Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
44
Enrollment target

NCT00039273: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.

NCT00039273 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00039273, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target

Study Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic colorectal cancer.

Interventions

  • BIOLOGICAL panitumumab

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2002-07
Phase Phase 2
Jonsson Comprehensive Cancer Center

321 total trials

What the finished NCT00039273 record still lists

NCT00039273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which panitumumab is the first listed.

NCT00039273 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00039273 about?

NCT00039273 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic co...

What is the current status of trial NCT00039273?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2002-07.

What interventions are being tested in trial NCT00039273?

The interventions under investigation include: panitumumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00039273?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00039273's enrollment target sits among peer trials

44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00039273, the US trial registry maintained by the National Library of Medicine. NCT00039273 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.